C4 Therapeutics (CCCC) Enterprise Value (2019 - 2025)
C4 Therapeutics' Enterprise Value history spans 7 years, with the latest figure at -$248.5 million for Q4 2025.
- For Q4 2025, Enterprise Value fell 1.48% year-over-year to -$248.5 million; the TTM value through Dec 2025 reached -$248.5 million, down 1.48%, while the annual FY2025 figure was -$248.5 million, 1.48% down from the prior year.
- Enterprise Value reached -$248.5 million in Q4 2025 per CCCC's latest filing, down from -$191.9 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$191.9 million in Q3 2025 to a low of -$465.9 million in Q2 2021.
- Average Enterprise Value over 5 years is -$279.0 million, with a median of -$265.7 million recorded in 2023.
- The largest YoY upside for Enterprise Value was 44.77% in 2021 against a maximum downside of 332.79% in 2021.
- A 5-year view of Enterprise Value shows it stood at -$309.3 million in 2021, then increased by 10.71% to -$276.2 million in 2022, then rose by 8.14% to -$253.7 million in 2023, then rose by 3.46% to -$244.9 million in 2024, then fell by 1.48% to -$248.5 million in 2025.
- Per Business Quant, the three most recent readings for CCCC's Enterprise Value are -$248.5 million (Q4 2025), -$191.9 million (Q3 2025), and -$214.6 million (Q2 2025).